Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label study of AZD8055 in Japanese patients with advanced solid tumours
jRCT2080220891Phase 1
- Sponsor
- AstraZeneca
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azd8055 in Nonhematologic neoplasms, sponsored by AstraZeneca. Primary endpoint: Safety and tolerability of AZD8055.
02
Drugs
azd8055
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080220891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220891.